Mar 23, 2020   SOURCE: PR NewsWire

2020 Pipeline Insight on Insulin Resistance

DUBLIN, March 23, 2020 /PRNewswire/ -- The "Insulin Resistance - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

Insulin Resistance - Pipeline Insight, 2020 report outlays comprehensive insights of present scenario and growth prospects across Insulin Resistance. A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type.

Products covered by Phase

    --  Phase III, Phase II, Phase I
    --  Pre-clinical & Discovery
    --  Inactive (Discontinued and Dormant)

Reasons to Buy

    1. Establish a comprehensive understanding of the current pipeline scenario
       across Insulin Resistance to formulate effective R&D strategies
    2. Assess challenges and opportunities that influence Insulin Resistance R&D
    3. Gather impartial perspective of strategies of the emerging competitors
       having potentially lucrative portfolio in this space and create effective
       counter strategies to gain competitive advantage
    4. Identify the relationship between the product and use it for target
       finding, drug repurposing, and precision medicine
    5. Devise in licensing and out licensing strategies by identifying
       prospective partners with progressing projects for Insulin Resistance to
       enhance and expand business potential and scope
    6. Our extensive domain knowledge on therapy areas support the client in
       decision-making process regarding their therapeutic portfolio by
       identifying the reason behind the inactive or discontinued drugs

Overview of pipeline development activities for Insulin Resistance

Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.

Therapeutic segmentation of products for Insulin Resistance

The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this indication.

Methodology

Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts.

Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report

    --  Provides an overview of therapeutic pipeline activity for Insulin
        Resistance across the complete product development cycle including all
        clinical and non-clinical stages
    --  It comprises of detailed profiles of Insulin Resistance therapeutic
        products with key coverage of developmental activities including
        licensing & collaboration deals, patents issued, designations,
        technologies and chemical information
    --  Therapeutic assessment of the active pipeline products by stage, product
        type, molecule type, and route of administration

    --  Coverage of dormant and discontinued pipeline projects across Insulin
        Resistance

Key Topics Covered:

1. Report Introduction

2. Insulin Resistance - Disease Overview

3. Pipeline Outlook

    --  An Overview of Pipeline Products for Insulin Resistance

4. Comparative Analysis

5. Insulin Resistance Therapeutic Products in Clinical Stage
5.1 Drug Name : Company Name

    --  Product Description
    --  Research and Development
    --  Product Development Activities

6. Insulin Resistance Therapeutic Products in Non-clinical Stage
6.1 Drug Name : Company Name

    --  Product Description
    --  Research and Development
    --  Product Development Activities

7. Therapeutic Pipeline Analysis

    --  Pipeline Analysis by Route of Administration
    --  Pipeline Analysis by Stage and Route of Administration
    --  Pipeline Analysis by Molecule Type
    --  Pipeline Analysis by Stage and Molecule Type

8. Inactive Pipeline Products
8.1 Drug Description

    --  Research and Development Studies
    --  Product Development Activities
    --  Reason for dormancy/discontinuation

Companies Mentioned 

    --  Eisai Co Ltd
    --  Genentech
    --  ProMetic Life Sciences
    --  TWi Biotechnology
    --  Araim Pharmaceutical

    --  Aus Bio Limited

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/h9rmhz

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.


Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/2020-pipeline-insight-on-insulin-resistance-301028137.html

SOURCE Research and Markets